NEW YORK (GenomeWeb) – Foundation Medicine said today that it is entering a strategic collaboration with Novartis focused on developing companion diagnostic tests for the company's portfolio of targeted oncology and immuno-oncology drugs.

According to Foundation, the collaboration structure includes development, regulatory support and commercialization of CDx tests using its US Food and Drug Administration-approved comprehensive genomic profiling assay, FoundationOne CDx.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.